Medication adherence and the risk of severe asthma exacerbations: A systematic review

European Respiratory Journal

Volumn 45, Issue 2, 2015, Pages 396-407

  Engelkes, Marjolein ^a   Janssens, Hettie M ^b   De Jongste, Johan C ^b   Sturkenboom, Miriam C J M ^a   Verhamme, Katia M C ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b SOPHIA CHILDREN S HOSPITAL   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

FLUTICASONE; MONTELUKAST; ANTIASTHMATIC AGENT; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT;

ARTICLE; ASTHMA; CHILD HOSPITALIZATION; DISEASE ASSOCIATION; DISEASE EXACERBATION; DISEASE PREDISPOSITION; DISEASE SEVERITY; EMERGENCY TREATMENT; HIGH RISK BEHAVIOR; HUMAN; INCIDENCE; MEDICATION COMPLIANCE; RISK ASSESSMENT; RISK FACTOR; SYSTEMATIC REVIEW; TREATMENT OUTCOME; TREATMENT RESPONSE; ADULT; CHILD; FEMALE; MALE; NEBULIZER; PATHOPHYSIOLOGY;

ADRENERGIC BETA-2 RECEPTOR AGONISTS; ADULT; ANTI-ASTHMATIC AGENTS; ASTHMA; CHILD; FEMALE; HUMANS; MALE; MEDICATION ADHERENCE; NEBULIZERS AND VAPORIZERS; RISK FACTORS; TREATMENT OUTCOME;

EID: 84922136593     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00075614     Document Type: Article

References (63)

1. Pearce N, Aït-Khaled N, Beasley R, et al. Worldwide trends in the prevalence of asthma symptoms: phase III of the International Study of Asthma and Allergies in Childhood (ISAAC). Thorax 2007;62:758-766.
2. To T, Stanojevic S, Moores G, et al. Global asthma prevalence in adults: findings from the cross-sectional world health survey. BMC Public Health 2012;12:204.
3. Bender BG, Rand C. Medication non-adherence and asthma treatment cost. Curr Opin Allergy Clin Immunol 2004;4:191-195.
4. Bateman ED, Hurd SS, Barnes PJ, et al. Global strategy for asthma management and prevention: GINA executive summary. Eur Respir J 2008;31:143-178.
5. Choi TN, Westermann H, Sayles W, et al. Beliefs about asthma medications: patients perceive both benefits and drawbacks. J Asthma 2008;45:409-414.
6. Harrison B, Stephenson P, Mohan G, et al. An ongoing Confidential Enquiry into asthma deaths in the Eastern Region of the UK, 2001-2003. Prim Care Respir J 2005;14:303-313.
7. Horne R. Compliance, adherence, and concordance: implications for asthma treatment. Chest 2006;130:Suppl. 1, 65S-72S.
8. Côté I, Farris K, Feeny D. Is adherence to drug treatment correlated with health-related quality of life? Qual Life Res 2003;12:621-633.
9. Milgrom H, Bender B, Ackerson L, et al. Noncompliance and treatment failure in children with asthma. J Allergy Clin Immunol 1996;98:1051-1057.
10. Bender BG, Bender SE. Patient-identified barriers to asthma treatment adherence: responses to interviews, focus groups, and questionnaires. Immunol Allergy Clin North Am 2005;25:107-130.
11. Rand CS, Wise RA. Measuring adherence to asthma medication regimens. Am J Respir Crit Care Med 1994;149:S69-S76.
12. Williams LK, Joseph CL, Peterson EL, et al. Patients with asthma who do not fill their inhaled corticosteroids: a study of primary nonadherence. J Allergy Clin Immunol 2007;120:1153-1159.
13. Chan PW, DeBruyne JA. Parental concern towards the use of inhaled therapy in children with chronic asthma. Pediatr Int 2000;42:547-551.
14. Allen DB. Inhaled steroids for children: effects on growth, bone, and adrenal function. Endocrinol Metab Clin North Am 2005;34:555-564.
15. Peterson AM, Nau DP, Cramer JA, et al. A checklist for medication compliance and persistence studies using retrospective databases. Value Health 2007;10:3-12.
16. Reddel HK, Taylor DR, Bateman ED, et al. An official American Thoracic Society/European Respiratory Society statement: asthma control and exacerbations: standardizing endpoints for clinical asthma trials and clinical practice. Am J Respir Crit Care Med 2009;180:59-99.
17. Taylor DR, Bateman ED, Boulet LP, et al. A new perspective on concepts of asthma severity and control. Eur Respir J 2008;32:545-554.
18. Goodman M, Hays S. Asthma and swimming: a meta-analysis. J Asthma 2008;45:639-647.
19. Wells GA, Shea B, O'Connell D, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. www.ohri.ca/programs/clinical-epidemiology/oxford.asp
20. Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 2009;6:e1000097.
21. Rust G, Zhang S, Reynolds J. Inhaled corticosteroid adherence and emergency department utilization among Medicaid-enrolled children with asthma. J Asthma 2013;50:769-775.
22. Camargo CA Jr, Ramachandran S, Ryskina KL, et al. Association between common asthma therapies and recurrent asthma exacerbations in children enrolled in a state Medicaid plan. Am J Health Syst Pharm 2007;64:1054-1061.
23. Bukstein DA, Murphy KR, Katz LM, et al. Outcomes among a young population of pediatric asthma patients using controller therapies: results from a retrospective database analysis. Pediatr Asthma Allergy Immunol 2007;20:211-222.
24. Bukstein DA, Luskin AT, Bernstein A. "Real-world" effectiveness of daily controller medicine in children with mild persistent asthma. Ann Allergy Asthma Immunol 2003;90:543-549.
25. Elkout H, Helms PJ, Simpson CR, et al. Adequate levels of adherence with controller medication is associated with increased use of rescue medication in asthmatic children. PLoS One 2012;7:e39130.
26. Herndon JB, Mattke S, Evans Cuellar A, et al. Anti-inflammatory medication adherence, healthcare utilization and expenditures among Medicaid and children's health insurance program enrollees with asthma. Pharmacoeconomics 2012;30:397-412.
27. Price D, Thomas M, Haughney J, et al. Real-life comparison of beclometasone dipropionate as an extrafine- or larger-particle formulation for asthma. Respir Med 2013;107:987-1000.
28. Williams LK, Peterson EL, Wells K, et al. Quantifying the proportion of severe asthma exacerbations attributable to inhaled corticosteroid nonadherence. J Allergy Clin Immunol 2011;128:1185-1191.
29. Williams LK, Pladevall M, Xi H, et al. Relationship between adherence to inhaled corticosteroids and poor outcomes among adults with asthma. J Allergy Clin Immunol 2004;114:1288-1293.
30. Balkrishnan R, Christensen DB. Inhaled corticosteroid nonadherence and immediate avoidable medical events in older adults with chronic pulmonary ailments. J Asthma 2000;37:511-517.
31. Mattke S, Martorell F, Hong SY, et al. Anti-inflammatory medication adherence and cost and utilization of asthma care in a commercially insured population. J Asthma 2010;47:323-329.
32. Delea TE, Stanford RH, Hagiwara M, et al. Association between adherence with fixed dose combination fluticasone propionate/salmeterol on asthma outcomes and costs. Curr Med Res Opin 2008;24:3435-3442.
33. Stern L, Berman J, Lumry W, et al. Medication compliance and disease exacerbation in patients with asthma: a retrospective study of managed care data. Ann Allergy Asthma Immunol 2006;97:402-408.
34. McMahon AD, Lipworth BJ, Davey PG, et al. Continuity of prescribing with inhaled corticosteroids and control of asthma. Pharmacoepidemiol Drug Saf 2000;9:293-303.
35. Smith K, Warholak T, Armstrong E, et al. Evaluation of risk factors and health outcomes among persons with asthma. J Asthma 2009;46:234-237.
36. Hyland ME, Whalley B, Halpin DM, et al. Frequency of non-asthma GP visits predicts asthma exacerbations: an observational study in general practice. Prim Care Respir J 2012;21:405-411.
37. Osman LM, Friend JA, Legge JS, et al. Requests for repeat medication prescriptions and frequency of acute episodes in asthma patients. J Asthma 1999;36:449-457.
38. Rohan J, Drotar D, McNally K, et al. Adherence to pediatric asthma treatment in economically disadvantaged African-American children and adolescents: an application of growth curve analysis. J Pediatr Psychol 2010;35:394-404.
39. McNally KA, Rohan J, Schluchter M, et al. Adherence to combined montelukast and fluticasone treatment in economically disadvantaged African-American youth with asthma. J Asthma 2009;46:921-927.
40. Krishnan JA, Bender BG, Wamboldt FS, et al. Adherence to inhaled corticosteroids: an ancillary study of the Childhood Asthma Management Program clinical trial. J Allergy Clin Immunol 2012;129:112-118.
41. Lasmar L, Camargos P, Champs NS, et al. Adherence rate to inhaled corticosteroids and their impact on asthma control. Allergy 2009;64:784-789.
42. Santos Pde M, D'Oliveira A Jr, Noblat Lde A, et al. Preditores da adesão ao tratamento em pacientes com asma grave atendidos em um centro de referência na Bahia [Predictors of adherence to treatment in patients with severe asthma treated at a referral center in Bahia, Brazil]. J Bras Pneumol 2008;34:995-1002.
43. Martin BC, Wiley-Exley EK, Richards S, et al. Contrasting measures of adherence with simple drug use, medication switching, and therapeutic duplication. Ann Pharmacother 2009;43:36-44.
44. Desai M, Oppenheimer JJ. Medication adherence in the asthmatic child and adolescent. Curr Allergy Asthma Rep 2011;11:454-464.
45. Boulet LP, Vervloet D, Magar Y, et al. Adherence: the goal to control asthma. Clin Chest Med 2012;33:405-417.
46. Riekert KA, Butz AM, Eggleston PA, et al. Caregiver-physician medication concordance and undertreatment of asthma among inner-city children. Pediatrics 2003;111:e214-e220.
47. Krishnan JA, Riekert KA, McCoy JV, et al. Corticosteroid use after hospital discharge among high-risk adults with asthma. Am J Respir Crit Care Med 2004;170:1281-1285.
48. Hess LM, Raebel MA, Conner DA, et al. Measurement of adherence in pharmacy administrative databases: a proposal for standard definitions and preferred measures. Ann Pharmacother 2006;40:1280-1288.
49. Mattke S, Jain AK, Sloss EM, et al. Effect of disease management on prescription drug treatment: what is the right quality measure? Dis Manag 2007;10:91-100.
50. Steiner JF, Earnest MA. The language of medication-taking. Ann Intern Med 2000;132:926-930.
51. Inhaler Error Steering Committee, Price D, Bosnic-Anticevich S, et al. Inhaler competence in asthma: common errors, barriers to use and recommended solutions. Respir Med 2013;107:37-46.
52. Newman SP. Scintigraphic assessment of therapeutic aerosols. Crit Rev Ther Drug Carrier Syst 1993;10:65-109.
53. Laube BL, Janssens HM, de Jongh FH, et al. What the pulmonary specialist should know about the new inhalation therapies. Eur Respir J 2011;37:1308-1331.
54. Grover C, Armour C, Asperen PP, et al. Medication use in children with asthma: not a child size problem. J Asthma 2011;48:1085-1103.
55. Busse WW, Morgan WJ, Taggart V, et al. Asthma outcomes workshop: overview. J Allergy Clin Immunol 2012;129:Suppl. 3, S1-S8.
56. Helms PJ. "Real world" pragmatic clinical trials: what are they and what do they tell us?. Pediatr Allergy Immunol 2002;13:4-9.
57. Schmier JK, Leidy NK. The complexity of treatment adherence in adults with asthma: challenges and opportunities. J Asthma 1998;35:455-472.
58. Bousquet J, Schünemann HJ, Zuberbier T, et al. Development and implementation of guidelines in allergic rhinitis - an ARIA-GA2LEN paper. Allergy 2010;65:1212-1221.
59. Dales RE, Cakmak S, Judek S, et al. Influence of outdoor aeroallergens on hospitalization for asthma in Canada. J Allergy Clin Immunol 2004;113:303-306.
60. Smyth AR, Barbato A, Beydon N, et al. Respiratory medicines for children: current evidence, unlicensed use and research priorities. Eur Respir J 2010;35:247-265.
61. Easterbrook PJ, Berlin JA, Gopalan R, et al. Publication bias in clinical research. Lancet 1991;337:867-872.
62. Schlender A, Alperin PE, Grossman HL, et al. Modeling the impact of increased adherence to asthma therapy. PLoS One 2012;7:e51139.
63. Forno E, Celedón JC. Predicting asthma exacerbations in children. Curr Opin Pulm Med 2012;18:63-69.